Antibiotic dose adjustment in the treatment of MRSA infections in patients with acute renal failure undergoing continuous renal replacement therapies;Dosificación de antibióticos en el tratamiento de las infecciones por SARM en pacientes con insuficiencia renal aguda sometidos a técnicas continuas de depuración extrarrenal

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 30, Issue 5, 2012, Pages 249-256

  Carcelero, Esther ^a   Soy, Dolors ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Antibiotics; Continuous renal replacement therapies; Haemodiafiltration; Haemodialysis; Haemofiltration; Pharmacokinetics

Indexed keywords

ANTIBIOTIC AGENT;

ACUTE KIDNEY FAILURE; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; DOSE RESPONSE; DRUG CLEARANCE; HIGH RISK PATIENT; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORBIDITY; MORTALITY; REVIEW;

ACETAMIDES; ACUTE KIDNEY INJURY; ANTI-BACTERIAL AGENTS; DRUG DOSAGE CALCULATIONS; GLYCOPEPTIDES; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; PRACTICE GUIDELINES AS TOPIC; RENAL REPLACEMENT THERAPY; STAPHYLOCOCCAL INFECTIONS;

EID: 84859917882     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2011.09.013     Document Type: Review

References (39)

1. G. Clermont, C.G. Acker, D.C. Angus, C.A. Sirio, M.R. Pinsky, and J.P. Johnson Renal failure in the ICU: comparison of the impact of acute renal failure and end-stage renal disease on ICU outcomes Kidney Int 62 2002 986 996
2. S. Uchino, J.A. Kellum, R. Bellomo, G.S. Doig, H. Morimatsu, and S. Morgera Acute renal failure in critically ill patients: a multinational, multicenter study JAMA 294 2005 813 818
3. M. Joy, G. Matzke, D. Amstrong, M.A. Marx, and B.J. Zarowitz A primer on continuous renal replacement therapy for critically ill patients Ann Pharmacother 32 1998 362 375
4. P. Zucchelli, and A. Santoro Dialysis-induced hypotension. A fresh look at pathophysiology Blood Purif 11 1993 85 98
5. Y.Y. Chen, F.D. Wang, C.Y. Liu, and P. Chou Incidence rate and variable cost of nosocomial infections in different types of intensive care units Infect Control Hosp Epidemiol 30 2009 39 46
6. A. Bueno-Cavanillas, M. Delgado-Rodríguez, A. López-Luque, S. Schaffino-Cano, and R. Gálvez-Vargas Influence of nosocomial infection on mortality rate in an intensive care unit Crit Care Med 22 1994 55 60
7. J.L. Vincent, J. Rello, J. Marshall, E. Silva, A. Anzueto, C.D. Martin EPIC II Group of Investigators Internacional study of the prevalence and outcomes of infection in intensive care units JAMA 302 2009 2323 2329
8. E. Rivers, B. Nguyen, S. Havstad, J. Ressler, A. Muzzin, and B. Knoblich Early goal-directed therapy in the treatment of severe sepsis and septic shock N Engl J Med 345 2001 1368 1377
9. J. Rodríguez-Baño, A.B. Millán, M.A. Domínguez, C. Borraz, M.P. González, and B. Almirante GEIH/GEMARA/REIPI. Impact of inappropriate empirical therapy for sepsis due to health care-associated methicillin-resistant Staphylococcus aureus J Infect 58 2009 131 137
10. S.E. Cosgrove, G. Sakoulas, E.N. Perencevich, M.J. Schwaber, A.W. Karchmer, and Y. Carmeli Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis Clin Infect Dis 36 2003 53 59
11. F. Pea, P. Viale, F. Pavan, and M. Furlanut Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy Clin Pharmacokinet 46 2007 997 1038
12. A.K. Meagher, P.G. Ambrose, T.H. Grasela, and E.J. Ellis-Grosse The pharmacokinetic and pharmacodynamic profile of tigecycline CID 41 Suppl 5 2005 S333 S340
13. Troy SM, Muralidharan G, Micalizzi M, Mojavarian P, Salacinski L, Raible D. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936) [abstract A-43]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology; 2003. p. 5.
14. R.L. Trotman, J.C. Williamson, D.M. Shoemaker, and W.L. Salzer Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy Clin Infect Dis 41 2005 1159 1166
15. D.T. Bearden Clinical pharmacokinetics of quinupristin/dalfopristin Clin Pharmacokinet 43 2004 239 252
16. G.R. Matzke, G.G. Zhanel, and D.R.P. Guay Clinical Pharmacokinetics of Vancomycin Clin Pharmacokinet 11 1986 257 282
17. M. Rowland Clinical pharmacokinetics of teicoplanin Clin Pharmacokinet 18 1990 184 209
18. F.T. Boereboom, F.F. Ververs, P.J. Blankestijn, T.J. Savelkoul, and A. van Dijk Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients Intensive Care Med 25 1999 1100 1104
19. W.L. Macias, B.A. Mueller, and S.K. Scarim Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance Clin Pharmacol Ther 50 1991 688 694
20. W. Chaijamorn, A. Jitsurong, K. Wiwattanawongsa, U. Wanakamanee, and P. Dandecha Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients Int J Antimicrob Agents 38 2011 152 156
21. S. Uchino, L. Cole, H. Morimatsu, D. Goldsmith, and R. Bellomo Clearance of vancomycin during high-volume haemofiltration: impact of pre-dilution Intensive Care Med 28 2002 1664 1667
22. M.E. DelDot, J. Lipman, and S.E. Tett Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration Br J Clin Pharmacol 58 2004 259 268
23. C. Santré, O. Leroy, M. Simon, H. Georges, B. Guery, and C. Beuscart Pharmacokinetics of vancomycin during continuous hemodiafiltration Intensive Care Med 19 1993 347 350
24. K. Yagasaki, S. Gando, N. Matsuda, T. Kameue, T. Ishitani, and T. Hirano Pharmacokinetics of teicoplanin in critically ill patients undergoing continuous hemodiafiltration Intensive Care Med 29 2003 2094 2095
25. R. Bellmann, G. Falkensammer, C. Seger, S. Weiler, J. Kountchev, and M. Joannidis Teicoplanin pharmacokinetics in critically ill patients on continuous veno-venous hemofiltration Int J Clin Pharmacol Ther 48 2010 243 249
26. F. Pea, L. Brollo, M. Lugano, L. Dal Pos, and M. Furlanut Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration Ther Drug Monit 23 2001 587 588
27. A. Chakraborty, S. Roy, J. Loeffler, and R.L. Chaves Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection J Antimicrob Chemother 64 2009 151 158
28. D. Khadzhynov, C. Joukhadar, and H. Peters Plasma and peritoneal dialysate levels during daptomycin therapy for peritonitis Am J Kidney Dis 53 2009 911 912
29. J.T. Kielstein, C. Eugbers, S.M. Bode-Boeger, J. Martens-Lobenhoffer, H. Haller, and C. Joukhadar Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis - a pharmacokinetic study Nephrol Dial Transplant 25 2010 1537 1541
30. A.M. Vilay, M. Grio, D.D. Depestel, K.M. Sowinski, L. Gao, and M. Heung Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis Crit Care Med 39 2011 19 25
31. D.J. Stalker, G.L. Jungbluth, N.K. Hopkins, and D.H. Batts Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers J Antimicrob Chemother 51 2003 1239 1246
32. D.J. Stalker, and G.L. Jungbluth Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial Clin Pharmacokinet 42 2003 1129 1140
33. B. Meyer, G.V. Kornek, M. Nikfardjam, G.D. Karth, G. Heinz, and G.J. Locker Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration J Antimicrob Chemother 56 2005 172 179
34. F. Pea, P. Viale, M. Lugano, F. Pavan, L. Scudeller, and G. Della Rocca Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases Am J Kidney Dis 44 2004 1097 1102
35. E. Fiaccadori, U. Maggiore, C. Rotelli, R. Giacosa, E. Parenti, and E. Picetti Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure Crit Care Med 32 2004 2437 2442
36. L.S. Mauro, C.A. Peloquin, K. Schmude, R. Assaly, and D. Malhotra Clearance of linezolid via continuous venovenous hemodiafiltration Am J Kidney Dis 47 2006 e83 e86
37. M.D. Kraft, D.A. Pasko, D.D. DePestel, J.J. Ellis, C.A. Peloquin, and B.A. Mueller Linezolid clearance during continuous venovenous hemodiafiltration: a case report Pharmacotherapy 23 2003 1071 1075
38. Carcelero E, Soy D, Guerrero L, Poch E, Fernández J, Castro P, et al. Linezolid pharmacokinetics in patients with acute renal failure undergoing continuous venovenous hemodiafiltration. J Clin Pharmacol. 2011. (en prensa).
39. I. Curkovic, B. Lüthi, D. Franzen, A. Ceschi, A. Rudiger, and N. Corti Trimethoprim/Sulfamethoxazole pharmacokinetics in two patients undergoing continuous venovenous hemodiafiltration Ann Pharmacother 44 2010 1669 1672